Zoetis Inc. $ZTS Shares Sold by Bridges Investment Management Inc.

Bridges Investment Management Inc. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 33.6% in the fourth quarter, HoldingsChannel reports. The firm owned 172,730 shares of the company’s stock after selling 87,391 shares during the quarter. Bridges Investment Management Inc.’s holdings in Zoetis were worth $21,733,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the third quarter worth about $31,000. Holos Integrated Wealth LLC acquired a new stake in Zoetis during the fourth quarter worth about $32,000. Finally, Elyxium Wealth LLC acquired a new stake in Zoetis during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $76.42 on Wednesday. The stock has a market capitalization of $32.04 billion, a price-to-earnings ratio of 12.67, a PEG ratio of 1.27 and a beta of 0.75. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a 50-day moving average of $103.52 and a 200 day moving average of $116.71.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Insider Buying and Selling

In other news, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several analyst reports. Bank of America raised their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Stifel Nicolaus dropped their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. Finally, Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $133.92.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms issued reminders and deadline notices tied to an ongoing securities fraud class action against Zoetis, alleging investors were harmed by false or misleading statements during the Jan. 14, 2025 to May 6, 2026 period. These headlines can weigh on sentiment because they raise legal overhang and potential financial/reputational risk.
• Negative Sentiment: Zoetis was reportedly downgraded after a steep broader market selloff, signaling weakening near-term sentiment from Wall Street and adding to pressure on the stock.
• Negative Sentiment: A bearish article highlighted lawsuits challenging the company’s companion-animal outlook, suggesting investors may be questioning growth assumptions for a key business segment.
• Neutral Sentiment: Zoetis presented at the 46th Annual William Blair Growth Stock Conference, which may help investors gauge management’s outlook and strategy, but no major new catalyst was highlighted in the transcript headline.
• Neutral Sentiment: One valuation-oriented piece argued Zoetis could be a deep-value opportunity with significant upside, which may support longer-term sentiment but is unlikely to outweigh today’s legal and rating-related headlines.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.